United States · Platforms & data · MarketBeat

Amgen's IMDELLTRA Cuts Death Risk 58% in Small-Cell Lung Cancer Study

Published by MarketBeat · United States 2 h ago

Amgen (NASDAQ:AMGN) presented Phase III data at the European Society for Medical Oncology Congress 2026 showing that its DLL3-targeting BiTE therapy IMDELLTRA, when added to…

Read the full article on MarketBeat Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.marketbeat.com)

Also worth reading

The Motley Fool

My father-in-law, 81, sold his $75,000 home to pay his daughter’s $50,000 debt. How can I keep him from becoming destitute?

Yahoo Finance

Hercules Capital (HTGC) Stock Still Looks Undervalued After A 63% Five Year Run

TheStreet

Amgen's IMDELLTRA Cuts Death Risk 58% in Small-Cell Lung Cancer Study

Share

Also worth reading

1 Red Flag That Keeps Me From Buying AMD Stock

Yemen’s Houthis renew threat against Riyadh airport as flights set to resume

Musk says Ukraine violated Starlink terms with offensive drone strikes

My father-in-law, 81, sold his $75,000 home to pay his daughter’s $50,000 debt. How can I keep him from becoming destitute?

Hercules Capital (HTGC) Stock Still Looks Undervalued After A 63% Five Year Run

Bank of America resets Tesla forecast as Robotaxi miles double